225 related articles for article (PubMed ID: 17890451)
1. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.
Herling M; Patel KA; Teitell MA; Konopleva M; Ravandi F; Kobayashi R; Jones D
Blood; 2008 Jan; 111(1):328-37. PubMed ID: 17890451
[TBL] [Abstract][Full Text] [Related]
2. [Transgenic mice expressing MTCP1: an animal model for T-cell prolymphocytic leukemia].
Chiali-Gritti C
Ann Pharm Fr; 2000 Jan; 58(1):54-61. PubMed ID: 10669814
[TBL] [Abstract][Full Text] [Related]
3. Proto-oncogene TCL1: more than just a coactivator for Akt.
Noguchi M; Ropars V; Roumestand C; Suizu F
FASEB J; 2007 Aug; 21(10):2273-84. PubMed ID: 17360849
[TBL] [Abstract][Full Text] [Related]
4. T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation.
Hoyer KK; Herling M; Bagrintseva K; Dawson DW; French SW; Renard M; Weinger JG; Jones D; Teitell MA
J Immunol; 2005 Jul; 175(2):864-73. PubMed ID: 16002684
[TBL] [Abstract][Full Text] [Related]
5. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
[TBL] [Abstract][Full Text] [Related]
6. Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
Oberbeck S; Schrader A; Warner K; Jungherz D; Crispatzu G; von Jan J; Chmielewski M; Ianevski A; Diebner HH; Mayer P; Kondo Ados A; Wahnschaffe L; Braun T; Müller TA; Wagle P; Bouska A; Neumann T; Pützer S; Varghese L; Pflug N; Thelen M; Makalowski J; Riet N; Göx HJM; Rappl G; Altmüller J; Kotrová M; Persigehl T; Hopfinger G; Hansmann ML; Schlößer H; Stilgenbauer S; Dürig J; Mougiakakos D; von Bergwelt-Baildon M; Roeder I; Hartmann S; Hallek M; Moriggl R; Brüggemann M; Aittokallio T; Iqbal J; Newrzela S; Abken H; Herling M
Blood; 2020 Dec; 136(24):2786-2802. PubMed ID: 33301031
[TBL] [Abstract][Full Text] [Related]
7. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin.
Herling M; Teitell MA; Shen RR; Medeiros LJ; Jones D
Blood; 2003 Jun; 101(12):5007-9. PubMed ID: 12576313
[TBL] [Abstract][Full Text] [Related]
8. Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype.
Toyota S; Nakamura N; Dan K
Int J Hematol; 2005 Jan; 81(1):66-8. PubMed ID: 15717692
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family.
Laine J; Künstle G; Obata T; Noguchi M
J Biol Chem; 2002 Feb; 277(5):3743-51. PubMed ID: 11707444
[TBL] [Abstract][Full Text] [Related]
10. IL-2-induced growth of CD8+ T cell prolymphocytic leukemia cells mediated by NF-kappaB induction and IL-2 receptor alpha expression.
Arima N; Matsushita K; Suruga Y; Ohtsubo H; Fujiwara H; Hidaka S; Arimura K; Kukita T; Yamaguchi K; Fukumori J; Tanaka H
Leuk Res; 1998 Mar; 22(3):265-73. PubMed ID: 9619918
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of mature T-cell leukemia.
Pekarsky Y; Hallas C; Croce CM
JAMA; 2001 Nov; 286(18):2308-14. PubMed ID: 11710897
[TBL] [Abstract][Full Text] [Related]
12. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1.
Künstle G; Laine J; Pierron G; Kagami Si S; Nakajima H; Hoh F; Roumestand C; Stern MH; Noguchi M
Mol Cell Biol; 2002 Mar; 22(5):1513-25. PubMed ID: 11839817
[TBL] [Abstract][Full Text] [Related]
13. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
Sun S; Fang W
Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
[TBL] [Abstract][Full Text] [Related]
14. The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways.
Despouy G; Joiner M; Le Toriellec E; Weil R; Stern MH
Blood; 2007 Dec; 110(13):4406-16. PubMed ID: 17846228
[TBL] [Abstract][Full Text] [Related]
15. The protooncogene TCL1 is an Akt kinase coactivator.
Laine J; Künstle G; Obata T; Sha M; Noguchi M
Mol Cell; 2000 Aug; 6(2):395-407. PubMed ID: 10983986
[TBL] [Abstract][Full Text] [Related]
16. T cell receptor-stimulated generation of hydrogen peroxide inhibits MEK-ERK activation and lck serine phosphorylation.
Kwon J; Devadas S; Williams MS
Free Radic Biol Med; 2003 Aug; 35(4):406-17. PubMed ID: 12899942
[TBL] [Abstract][Full Text] [Related]
17. Comparison of karyotyping,
Sun Y; Tang G; Hu Z; Thakral B; Miranda RN; Medeiros LJ; Wang SA
J Clin Pathol; 2018 Apr; 71(4):309-315. PubMed ID: 28821581
[TBL] [Abstract][Full Text] [Related]
18. A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane.
French SW; Shen RR; Koh PJ; Malone CS; Mallick P; Teitell MA
Biochemistry; 2002 May; 41(20):6376-82. PubMed ID: 12009899
[TBL] [Abstract][Full Text] [Related]
19. Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia.
Braun T; Stachelscheid J; Bley N; Oberbeck S; Otte M; Müller TA; Wahnschaffe L; Glaß M; Ommer K; Franitza M; Gathof B; Altmüller J; Hallek M; Auguin D; Hüttelmaier S; Schrader A; Herling M
Cancer Res; 2022 May; 82(9):1818-1831. PubMed ID: 35259248
[TBL] [Abstract][Full Text] [Related]
20. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia.
Gritti C; Dastot H; Soulier J; Janin A; Daniel MT; Madani A; Grimber G; Briand P; Sigaux F; Stern MH
Blood; 1998 Jul; 92(2):368-73. PubMed ID: 9657733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
